Rocky Mountain Spotted Fever in a Large Metropolitan Center, Mexico–United States Border, 2009–2019
Oscar E. Zazueta
, Paige A. Armstrong, Adriana Márquez-Elguea, Néstor Saúl Hernández Milán, Amy E. Peterson, Diego F. Ovalle-Marroquín, Maria Fierro, Rodolfo Arroyo-Machado, Moises Rodriguez-Lomeli, Guillermo Trejo-Dozal, and Christopher D. Paddock
Author affiliations: Secretariat of Health of Baja California (Instituto de Servicios de Salud Pública del Estado de Baja California), Mexicali, Mexico (O.E. Zazueta, A. Márquez-Elguea, N.S.H. Milán, D.F. Ovalle-Marroquín, R. Arroyo-Machado, M. Rodriguez-Lomeli, G. Trejo-Dozal); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.A. Armstrong, A.E. Peterson, C.D. Paddock); Imperial Country Public Health Department, El Centro, California, USA (M. Fierro)
Figure 1. Flowchart used to determine case status of patients in whom Rocky Mountain spotted fever was diagnosed, Mexicali, Mexico, 2009–2019. DGE, Directorate General of Epidemiology; IFA, indirect immunofluorescence antibody assay; RMSF, Rocky Mountain spotted fever.
Page created: April 15, 2021
Page updated: May 20, 2021
Page reviewed: May 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.